Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Most relevant
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASTELLAS PHARMA INC.
2016ASTELLAS PHARMA : World Anti-Doping Agency and Astellas Announce Global Initiati..
PU
2016ASTELLAS PHARMA : Chromocell and Astellas Announce FDA Fast Track Designation an..
PU
2016Chromocell and Astellas Announce FDA Fast Track Designation and First Subject..
CI
2016ASTELLAS PHARMA : Filed Lawsuit against Patent Infringement of Myrbetriq« in the..
PU
2016Astellas Pharma Inc. Announces Executive Appointments
CI
2016Astellas Pharma Inc. Receives Approval for Kiklin Granules, a Treatment for H..
CI
2016Maruho Co., Ltd. and Astellas Pharma Inc. Enter into an Exclusive License Agr..
CI
2016ASTELLAS PHARMA : Receives Approval for Kiklin« Granules, a Treatment for Hyperp..
PU
2016ASTELLAS PHARMA : Approval for Manufacturing and Marketing of "Micatrio« Combina..
PU
2016ASTELLAS PHARMA INC : Ex-dividend day for interim dividend
FA
2016Vical and Astellas Announce Topline Results from a Phase 2 Study of Investiga..
CI
2016ASTELLAS PHARMA : Selected as a Dow Jones Sustainability Asia Pacific Index Comp..
PU
2016Courtagen Life Sciences Collaborates with Astellas Pharma for Mitochondrial D..
CI
2016ASTELLAS PHARMA : Announces Personnel Changes (pdf 47KB)
PU
2016Pfizer boosts cancer drug roster with $14 billion Medivation deal
RE
2016Pfizer boosts cancer drug roster with $14 billion Medivation deal
RE
2016Astellas Submits New Drug Application for Extended-Release Tablets of Quetiap..
CI
2016ASTELLAS PHARMA : Announces Transfer of U.S. Manufacturing Subsidiary to Avara (..
PU
2016ASTELLAS PHARMA : Reports First Quarter Financial Results of FY2016 (pdf 164KB)
PU
2016ASTELLAS PHARMA : Reports First Quarter Financial Results of FY2016
BU
2016Astellas Pharma, Inc. Announces Consolidated Earnings Results for the First Q..
CI
2016Astellas Pharma Inc. and DigiTx Partners LLC Launches DigiTx Partners in Part..
CI
2016DidgiTx Partners Seeks Acquisitions
CI
2016Lupin Reportedly In Talks To Acquire Medicine Brands From Astellas And Shiono..
CI
2016ASTELLAS PHARMA : and FibroGen Announce First Patient Treated in Phase 3 Studies..
PU
2016Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and P..
CI
2016Astellas Promotes John Demaree to Vice President of Oncology Marketing in Ame..
CI
2016Astellas Names Joseph Devaney as Vice President, Government Affairs and Polic..
CI
2016ASTELLAS PHARMA : Named to FTSE4Good Sustainability Index for the Fifth Consecut..
PU
2016Shionogi & Astellas To Sell Its Drug Brands
CI
2016Astellas Launches New Latin America Affiliate in Colombia; Appoints Sandra Ci..
CI
2016Institute of Medical Science, University of Tokyo and Astellas Enter into New..
CI
2016ASTELLAS PHARMA : The Institute of Medical Science, the University of Tokyo and ..
PU
2016Excelra Enters into Drug Repurposing Collaboration with Astellas Pharma Inc
CI
2016GENENTECH, OSI TO PAY $67 MILLION OV : U.S. Justice Dept
RE
2016ASTELLAS PHARMA : AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PAT..
PU
2016Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients ..
CI
2016Astellas Pharma, Inc. Announces Management Changes
CI
2016ASTELLAS PHARMA : THE RESULTS FROM A ONE YEAR TREATMENT OF REPATHA PRESENTED AT ..
PU
2016Astellas Pharma, Inc. Reports Consolidated Earnings Results for the Fourth Qu..
CI
2016Medivation succumbs to pressure to explore sale - sources
RE
2016EXCLUSIVE : Medivation succumbs to pressure to explore sale - sources
RE
2016EXCLUSIVE - MEDIVATION SUCCUMBS TO P : sources
RE
2016Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation
RE
2016ASTELLAS PHARMA : Amgen astellas biopharma and astellas introduce repatha« (evol..
PU
2016ASTELLAS PHARMA : CHMP Issues Positive Opinion to Include New Data in European L..
PU
2016ASTELLAS PHARMA : Certain media coverage related to Astellas
PU
2016ASTELLAS PHARMA : Enters a New Collaborative Research Agreement with AIST to Dis..
PU
2016ASTELLAS PHARMA : Establishment and Start of Operations of Malaysia Subsidiary a..
PU
2016ASTELLAS PHARMA : and LEO Pharma Close Transaction to Transfer Global Dermatolog..
PU
2016ASTELLAS PHARMA INC : Ex-dividend day for final dividend
FA
2016ASTELLAS PHARMA : and Mitsubishi Tanabe Pharma Execute Agreement for Share of Co..
PU
2016ASTELLAS PHARMA : Pivotal Phase III Trial of enzalutamide Initiated in Metastati..
PU
2016ASTELLAS PHARMA : Positive top-line results from phase 3 study evaluating romoso..
PU
2016ASTELLAS PHARMA : Selected as a Nadeshiko Brand Component for Excellence in Prov..
PU
2016ASTELLAS PHARMA : Announces Personnel Changes (pdf 47KB)
PU
2016ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 92KB)
PU
2016ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 41KB)
PU
2016ASTELLAS PHARMA : Announces Management Structure Change (pdf 70KB)
PU
2016ASTELLAS PHARMA : Announces Personnel Changes and Organizational Change (pdf 47K..
PU
2016ASTELLAS PHARMA : Receives Approval for a Supplemental New Drug Application for ..
PU
2016ASTELLAS PHARMA : Submits New Drug Application for Linaclotide, Treatment for Ir..
PU
2016ASTELLAS PHARMA : POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMA..
PU
2016ASTELLAS PHARMA : FDA Accepts For Review Supplemental New Drug Application for X..
PU
2016ASTELLAS PHARMA : Announces Results of Tender Offer to Acquire All Outstanding S..
PU
2016ASTELLAS PHARMA : Announces Personnel Changes and Organizational Changes (pdf 57..
PU
2016ASTELLAS PHARMA : and CLINO Announce License Agreement to Develop and Commercial..
PU
2016ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 139KB)
PU
2016ASTELLAS PHARMA : Extends Tender Offer to Acquire All Outstanding Shares of Ocat..
PU
2016ASTELLAS PHARMA : REPATHA« (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAP..
PU
2016ASTELLAS PHARMA : Extension of agreement on Telmisartan (Micardis« family) (pdf ..
PU
2015ASTELLAS PHARMA : Extends Tender Offer to Acquire All Outstanding Shares of Ocat..
PU
2015ASTELLAS PHARMA : Presentation material for Press Conference on December 8 (pdf ..
PU
2015ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 46KB)
PU
2015ASTELLAS PHARMA : Announces Personnel Change (pdf 46KB)
PU
Prev.4  5  6  7  8   9  10  11  12  13Next
Upcoming event on ASTELLAS PHARMA INC.